Catalogue preview · final packaging and presentation may vary if stockedFive choices across your ballotUse votes only for compounds you would consider ordering
One vote per compoundEach candidate can be selected once on this browser
Flexible interest signalRemove or reassign a vote whenever you like
SURVODUTIDE
Survodutide is an investigational single molecule that activates GLP-1 and glucagon receptors. Its development programme studies both body-weight and liver-disease questions, reflecting the different biology contributed by the two receptors.
Loading your saved choices…
SURVODUTIDE is currently being evaluated through customer voting and is not available to order. Final product specifications and batch documentation will be published only if it joins the catalogue.
This page records catalogue interest only. If SURVODUTIDE is selected for supply, Puffin will publish the confirmed format, batch documentation, and laboratory preparation information on the product listing.
Storage and handling requirements depend on the final supplied format. Confirmed instructions will be provided with the batch details if this candidate is added to the catalogue.
Understanding Survodutide
Explore the science, research focus, and key information behind this compound.
What is Survodutide?+
Survodutide is a useful comparison compound when GLP-1 and glucagon pathways share the research question.
What Researchers Study+
Researchers examine GLP-1 and glucagon activity, Energy-balance models, and Dual-agonist comparisons.
How Survodutide Works+
GLP-1-receptor activity contributes food-intake and glucose-dependent signalling; glucagon-receptor activity adds hepatic and energy-metabolism effects. In plain language, the dual design aims to combine appetite-related and liver/energy pathways in one balanced molecule.
Research at a Glance+
Clinical signals have been reported in obesity and MASH programmes. Randomized trials of the sponsor’s defined survodutide product reported body-weight and liver-disease signals. Trial population, titration, estimand, and product identity are part of those results. Read the peer-reviewed MASH trial. Topline success is not yet an approval. Sponsor-reported late-stage results are important development news, but full peer-reviewed analyses and regulatory review remain separate steps. Same receptor pair does not make mazdutide identical. Survodutide and mazdutide both target GLP-1 and glucagon receptors, but molecular structure, receptor balance, exposure, and clinical programmes differ.
If this candidate is added to the catalogue, it would be offered for controlled laboratory research only. It is not for human consumption and is not represented as a medicine, treatment, supplement, or substitute for an approved product.